215 related articles for article (PubMed ID: 28667893)
1. Amphipathic dextran-doxorubicin prodrug micelles for solid tumor therapy.
Jin R; Guo X; Dong L; Xie E; Cao A
Colloids Surf B Biointerfaces; 2017 Oct; 158():47-56. PubMed ID: 28667893
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer.
Zhou Y; Wang S; Ying X; Wang Y; Geng P; Deng A; Yu Z
Int J Nanomedicine; 2017; 12():6153-6168. PubMed ID: 28883726
[TBL] [Abstract][Full Text] [Related]
3. Acid-sensitive dextran prodrug: A higher molecular weight makes a better efficacy.
Li D; Han J; Ding J; Chen L; Chen X
Carbohydr Polym; 2017 Apr; 161():33-41. PubMed ID: 28189244
[TBL] [Abstract][Full Text] [Related]
4. Redox-Responsive Amphipathic Dextran Nanomicelles for Solid Tumor Therapy.
Song Y; Lou B; Cheng J; Zhao P; Lin C; Wen X
J Biomed Nanotechnol; 2016 Dec; 12(12):2083-96. PubMed ID: 29368837
[TBL] [Abstract][Full Text] [Related]
5. A bottlebrush-architectured dextran polyprodrug as an acidity-responsive vector for enhanced chemotherapy efficiency.
Zhang T; Wang Y; Ma X; Hou C; Lv S; Jia D; Lu Y; Xue P; Kang Y; Xu Z
Biomater Sci; 2020 Jan; 8(1):473-484. PubMed ID: 31755481
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antitumor activity of stearate-g-dextran micelles for intracellular doxorubicin delivery.
Du YZ; Weng Q; Yuan H; Hu FQ
ACS Nano; 2010 Nov; 4(11):6894-902. PubMed ID: 20939508
[TBL] [Abstract][Full Text] [Related]
7. Free Adriamycin-Loaded pH/Reduction Dual-Responsive Hyaluronic Acid-Adriamycin Prodrug Micelles for Efficient Cancer Therapy.
Yin T; Wang Y; Chu X; Fu Y; Wang L; Zhou J; Tang X; Liu J; Huo M
ACS Appl Mater Interfaces; 2018 Oct; 10(42):35693-35704. PubMed ID: 30259743
[TBL] [Abstract][Full Text] [Related]
8. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
[TBL] [Abstract][Full Text] [Related]
9. Poly(2-ethyl-2-oxazoline)-doxorubicin conjugate-based dual endosomal pH-sensitive micelles with enhanced antitumor efficacy.
Li J; Zhou Y; Li C; Wang D; Gao Y; Zhang C; Zhao L; Li Y; Liu Y; Li X
Bioconjug Chem; 2015 Jan; 26(1):110-9. PubMed ID: 25506713
[TBL] [Abstract][Full Text] [Related]
10. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
11. Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Wu Z; Li S; Cai Y; Chen F; Chen Y; Luo X
Colloids Surf B Biointerfaces; 2020 May; 189():110741. PubMed ID: 32032928
[TBL] [Abstract][Full Text] [Related]
12. A pH-responsive prodrug delivery system self-assembled from acid-labile doxorubicin-conjugated amphiphilic pH-sensitive block copolymers.
Huang X; Liao W; Xie Z; Chen D; Zhang CY
Mater Sci Eng C Mater Biol Appl; 2018 Sep; 90():27-37. PubMed ID: 29853091
[TBL] [Abstract][Full Text] [Related]
13. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.
Sun JJ; Chen YC; Huang YX; Zhao WC; Liu YH; Venkataramanan R; Lu BF; Li S
Acta Pharmacol Sin; 2017 Jun; 38(6):823-834. PubMed ID: 28504251
[TBL] [Abstract][Full Text] [Related]
14. Sialic-Acid-Anchored Micelles: A Hierarchical Targeting Device for Enhanced Tumor Tissue Accumulation and Cellular Internalization.
Zhu ML; Xu XL; Wang XJ; Zhang NN; Lu KJ; Qi J; Jin FY; Liu D; Du YZ
Mol Pharm; 2018 Sep; 15(9):4235-4246. PubMed ID: 30110551
[TBL] [Abstract][Full Text] [Related]
15. pH-sensitive doxorubicin-conjugated prodrug micelles with charge-conversion for cancer therapy.
Ma B; Zhuang W; Wang Y; Luo R; Wang Y
Acta Biomater; 2018 Apr; 70():186-196. PubMed ID: 29452272
[TBL] [Abstract][Full Text] [Related]
16. Amphiphilic polycarbonate conjugates of doxorubicin with pH-sensitive hydrazone linker for controlled release.
Jiang T; Li YM; Lv Y; Cheng YJ; He F; Zhuo RX
Colloids Surf B Biointerfaces; 2013 Nov; 111():542-8. PubMed ID: 23893028
[TBL] [Abstract][Full Text] [Related]
17. pH and redox dual-sensitive polysaccharide nanoparticles for the efficient delivery of doxorubicin.
Yang S; Tang Z; Zhang D; Deng M; Chen X
Biomater Sci; 2017 Sep; 5(10):2169-2178. PubMed ID: 28914292
[TBL] [Abstract][Full Text] [Related]
18. Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy.
Li D; Su T; Ma L; Yin F; Xu W; Ding J; Li Z
Eur J Med Chem; 2020 Aug; 199():112367. PubMed ID: 32474350
[TBL] [Abstract][Full Text] [Related]
19. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
[TBL] [Abstract][Full Text] [Related]
20. Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy.
Gu Y; Zhong Y; Meng F; Cheng R; Deng C; Zhong Z
Biomacromolecules; 2013 Aug; 14(8):2772-80. PubMed ID: 23777504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
